Use access key #2 to skip to page content.
$0.41 -0.04 (-8.89%)
11/21/2008 3:59 PM

EXACT Sciences Corp (EXAS)

CAPS Rating:
*****

An applied genomics company that develops proprietary DNA-based technologies for use in the detection of cancer.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

Ticker Not Ratable

EXAS doesn't currently meet the $100M market cap / $1.50 stock price minimum. (Learn More)

What the Community Thinks

Total Members

29 Outperforms
0 Underperforms
 

All-Stars

8 Outperforms
0 Underperforms
 

Members bullish on EXAS are also bullish on:

  • None

Members bearish on EXAS are also bearish on:

  • None

Ticker Tags

Micro Cap (5043), Biotechnology (230)
Suggest a tag

EXACT Sciences Corp At A Glance

Current Price: $0.41
Last Trade Time: 11/21/2008 3:59 PM
Open: $0.44
Previous Close: $0.45
Daily Range: $0.22 - $0.47
52-Week Range: $0.27 - $4.62
Volume: 32,333
Market Cap: $12.26M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

EXAS VS S&P 500 (SPY)

News & Discussion Boards

Other News Headlines for EXAS

More Headlines...

Top Bull Pitch

Recs

3

EXACT Sciences Corp (EXAS)

Avatar wymichael (< 20) Submitted: 11/02/07 7:28 PM

Let's see, would you prefer an invasive test for colon cancer, or a non-invasive one?

Replies: 0 | Reply | Permalink

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 6 :   1 2 Next »

Recs

0

 (EXAS)

Avatar kirkydu (99.67) Submitted: 12/20/07 11:40 AM : Outperform Start Price: $4.39 EXAS Score: -42.57

Company has large upside gap potential with a new screening test for colon cancer due several important decisions in the next few months.

Buy under 4 with spec money.

Report this Post Replies: 0 | Reply | Permalink

Recs

3

 (EXAS)

Avatar wymichael (< 20) Submitted: 11/02/07 7:28 PM : Outperform Start Price: $4.23 EXAS Score: -40.99

Let's see, would you prefer an invasive test for colon cancer, or a non-invasive one?

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (EXAS)

Avatar tharlow (61.15) Submitted: 10/25/07 7:39 PM : Outperform Start Price: $4.30 EXAS Score: -40.01

Ready to explode.

Report this Post Replies: 0 | Reply | Permalink

Recs

1

 (EXAS)

Avatar RationalAnarchy (< 20) Submitted: 10/16/07 11:01 AM : Outperform Start Price: $5.88 EXAS Score: -42.26

Solid product with a huge client-base...





Competitive advantage: yes


Uniqueness: (10 best) 7


Small Cap


Room to grow? Yes


Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (EXAS)

Avatar NitroDouglas (< 20) Submitted: 10/09/07 9:27 PM : Outperform Start Price: $4.60 EXAS Score: -39.69

With the former CEO of Exact Sciences being hired on by Labcorp, it seems as if there creating a tighter bond between both companies. The product is solid, version 2 of the Pre-Gen Plus looks to be in the 90% detection rate according to a study done by Mount Sinai School of Medicine. With this hard evidence as well as their acceptance of their medicare application in early 2008 could spark good things for Exact.


Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 6 :   1 2 Next »

Wall Street

There are no Wall Street tracker picks.

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners

Sponsored Links